Xiang Liu to Animals
This is a "connection" page, showing publications Xiang Liu has written about Animals.
Connection Strength
0.261
-
Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling. PLoS One. 2013; 8(10):e76593.
Score: 0.034
-
Interdiction of sphingolipid metabolism to improve standard cancer therapies. Adv Cancer Res. 2013; 117:1-36.
Score: 0.033
-
LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria. J Pharmacol Exp Ther. 2013 Jan; 344(1):167-78.
Score: 0.032
-
Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58.
Score: 0.026
-
Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009 Mar; 17(3):430-8.
Score: 0.025
-
Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 01; 13:2293-8.
Score: 0.023
-
The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther. 2007 Sep; 6(9):1455-60.
Score: 0.022
-
Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46.
Score: 0.021
-
Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis. Cytokine. 2020 11; 135:155219.
Score: 0.014
-
Bioactive sphingolipid profile in a xenograft mouse model of head and neck squamous cell carcinoma. PLoS One. 2019; 14(4):e0215770.
Score: 0.013
-
Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice. Int J Cancer. 2010 May 15; 126(10):2319-29.
Score: 0.007
-
Molecular targeting of acid ceramidase: implications to cancer therapy. Curr Drug Targets. 2008 Aug; 9(8):653-61.
Score: 0.006
-
Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther. 2007 Jul; 15(7):1259-63.
Score: 0.005